Physician profile
Daniel H Kellum
NPI 1174518625
$12,343.12
in general payments reported to CMS, 2019-2025
65 companies · $1,214 in 2025
The $1,214 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,421 · 2020: $1,673 · 2021: $2,204 · 2022: $2,522 · 2023: $1,591 · 2024: $1,718 · 2025: $1,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,511 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,510.75 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,118.79 | 2021-2025 | |
| Novo Nordisk INC | $1,510.58 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Allergan, INC. | $971.47 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $682.91 | 2019-2024 | Vaxneuvance, Gardasil 9, Pneumovax 23 |
| Astrazeneca Pharmaceuticals Lp | $591.04 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $557.13 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $489.74 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $414.91 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $306.82 | 2019-2025 | Shingrix, Arexvy, Blujepa |
| Pfizer INC. | $293.12 | 2019-2025 | |
| Avanir Pharmaceuticals, INC. | $291.84 | 2021-2022 | |
| Lilly USA, LLC | $277.25 | 2019-2024 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $271.71 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $269.33 | 2019-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $263.67 | 2020-2024 | Xarelto, Spravato |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kellum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.